Weight Regain After Stopping GLP-1 Medications: What Research Shows
Most people regain two-thirds of lost weight within one year of stopping GLP-1 drugs. Landmark trials on semaglutide and tirzepatide explain why, and what to do about it.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 28, 2026
Our medical review process ensures clinical accuracy and patient safety.
Why Stopping GLP-1 Medications Often Leads to Significant Weight Regain
One of the most common questions from patients beginning GLP-1 receptor agonist therapy is whether the results will last if they eventually stop treatment. Clinical trial data now offers a clear, if sobering, answer: for most people, a large fraction of the weight lost returns within 12 months of discontinuation.
Across multiple landmark trials involving semaglutide and tirzepatide, weight regain after stopping these medications is not the exception — it is the expected outcome. Understanding why this happens, how quickly it occurs, and what can be done to mitigate it is critical for anyone using or considering GLP-1 therapy for obesity management.
Evidence: "One year after withdrawal of semaglutide 2.4 mg, participants regained two-thirds of their prior weight loss, with similar reversals in cardiometabolic improvements." — Wilding JPH, et al. Diabetes, Obesity and Metabolism. 2022. DOI: 10.1111/dom.14725
The Biological Basis: Why the Body Fights Back
Weight regain after stopping GLP-1 agonists is not primarily a behavioral failure — it is a physiological response rooted in how the brain and gut regulate energy balance.
Appetite Hormone Rebound
GLP-1 receptor agonists work by mimicking the natural hormone GLP-1, which is released after meals to signal satiety, slow gastric emptying, and reduce appetite-promoting signals in the hypothalamus. When the medication is stopped:
- GLP-1 activity drops back to pre-treatment levels
- Ghrelin (the primary hunger hormone) returns to baseline
- Leptin resistance, which underlies obesity in many patients, resumes
The net result is that hunger increases, appetite suppression disappears, and caloric intake often rises back to pre-treatment patterns within weeks.
Metabolic Adaptation
Obesity medicine researchers have documented a phenomenon called "metabolic adaptation" — the tendency of resting metabolic rate to decrease after significant weight loss, making weight regain physiologically easier. This adaptation does not appear to be reversed by GLP-1 therapy alone, meaning the beneficial changes during treatment are largely dependent on the continued presence of the drug.
This is why weight regain after GLP-1 discontinuation mirrors what happens after other forms of induced weight loss, such as caloric restriction and bariatric surgery. Obesity is increasingly understood as a chronic, relapsing metabolic disease requiring long-term management, not a temporary condition resolved by a finite course of medication.
STEP 1 Extension: The Semaglutide Data
The clearest evidence for weight regain comes from the extension analysis of the STEP 1 trial, one of the pivotal studies that led to FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management.
Study Design
STEP 1 randomized 1,961 adults with obesity (BMI ≥ 30) or overweight with at least one comorbidity to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo, alongside lifestyle intervention. In the extension phase, all participants discontinued treatment and were followed for an additional 52 weeks (through week 120).
Key Results
| Outcome | Semaglutide Group (Week 120) | Placebo Group (Week 120) |
|---|---|---|
| Weight regain (relative to baseline) | +11.6% | +1.9% |
| Weight regain (relative to week 68) | +14.8% | +2.1% |
| Net weight loss maintained | ~5.6% | Similar to baseline |
| Cardiometabolic risk factors | Largely reversed | Remained at baseline |
Evidence: "At week 120, the group previously randomized to semaglutide had regained 11.6% body weight relative to baseline after the medication was withdrawn." — Wilding JPH, et al. Diabetes, Obesity and Metabolism. 2022. DOI: 10.1111/dom.14725
These numbers are striking: despite achieving approximately 15–17% weight loss during active treatment, participants who stopped semaglutide retained only about one-third of those gains one year later.
STEP 4: Continuous Treatment vs. Withdrawal
The STEP 4 trial was designed specifically to answer a related question: what happens to people who continue semaglutide versus those who switch to placebo after an initial period of weight loss?
Findings
Participants who had already lost weight during a 20-week run-in phase were randomized to either continue semaglutide 2.4 mg or switch to placebo for an additional 48 weeks. The divergence was dramatic:
- Continued semaglutide: Further weight loss, reaching a plateau at around 17.4% total reduction from baseline
- Switched to placebo: Progressive weight regain throughout the observation period
Evidence: "In participants who continued semaglutide, weight loss was not only maintained but continued; in those switched to placebo, weight regain was gradual and sustained over 48 weeks." — Rubino D, et al. JAMA. 2021;325(14):1414–1425. DOI: 10.1001/jama.2021.3224
The STEP 4 results reinforced the conclusion that sustained weight management with semaglutide requires ongoing treatment — not a defined course followed by medication withdrawal.
Tirzepatide: The SURMOUNT-4 Evidence
The pattern of weight regain extends to tirzepatide (Mounjaro/Zepbound), the dual GLP-1/GIP receptor agonist that achieves even greater weight loss than semaglutide monotherapy.
Main SURMOUNT-4 Trial
After 36 weeks of tirzepatide treatment at maximum tolerated doses (10 mg or 15 mg), participants were randomized to either continue tirzepatide or switch to placebo for 52 additional weeks.
Those who continued tirzepatide maintained their weight loss. Those who stopped regained weight rapidly, underscoring the same dependence on ongoing treatment observed with semaglutide.
Evidence: "Among participants with obesity who achieved weight reduction with tirzepatide, withdrawing treatment led to progressive weight regain in the majority, with concurrent reversal of cardiometabolic improvements." — Aronne LJ, et al. JAMA. 2024;331(1):38–48. DOI: 10.1001/jama.2023.24945
Post-Hoc Cardiometabolic Analysis
A 2025 post-hoc analysis of SURMOUNT-4 quantified the cardiovascular toll of weight regain after tirzepatide discontinuation. Among participants who stopped tirzepatide:
- 82.5% regained ≥25% of their initial weight loss within one year
- Greater weight regain was directly correlated with larger reversals in blood pressure, waist circumference, fasting glucose, and insulin resistance
- Cardiometabolic risk markers deteriorated in proportion to the amount of weight regained
Evidence: "By week 88, 82.5% of individuals who stopped tirzepatide had regained at least 25% of weight lost during the lead-in period, with proportional worsening of cardiometabolic parameters." — Post hoc SURMOUNT-4 analysis. JAMA Internal Medicine. 2025. DOI: 10.1001/jamainternmed.2025.6112
What the Meta-Analyses Show
Individual trials are consistent, and pooled analyses confirm the picture. A 2025 systematic review and meta-analysis published in Obesity Reviews examined discontinuation data across multiple GLP-1 receptor agonist trials.
Evidence: "Discontinuing GLP-1 receptor agonist therapy was associated with pooled mean weight regain of approximately 9.69 kg in patients prescribed semaglutide or tirzepatide, with reversal of cardiometabolic benefits appearing within months of stopping treatment." — Berg AS, et al. Obesity Reviews. 2025. DOI: 10.1111/obr.13929
The pattern across all GLP-1 agents — liraglutide, semaglutide, tirzepatide — is consistent: weight regain correlates with the magnitude of initial weight loss, happens rapidly, and largely reverses the cardiometabolic improvements achieved during therapy.
Speed and Timeline of Regain
Research suggests that weight regain after GLP-1 discontinuation is not gradual — it begins quickly:
- Most weight is regained within the first 12–20 weeks after stopping
- Hunger and appetite typically return to pre-treatment levels within days to weeks
- Full cardiometabolic regression can occur within 6–12 months
This timeline differs from what is seen after surgical weight loss, where regain is generally slower, likely because the structural changes from bariatric procedures (reduced stomach volume, altered gut anatomy) provide ongoing appetite suppression independent of medication.
Clinical Implications: When Stopping May Be Necessary
Despite the data, many patients do stop GLP-1 therapy — due to cost, insurance issues, side effects, pregnancy, or personal preference. When discontinuation is necessary, the following strategies may help minimize regain:
1. Gradual Dose Reduction
Rather than abrupt cessation, tapering the dose over 8–12 weeks may blunt the appetite rebound, though this approach has limited clinical trial support. Discuss options with your prescriber.
2. Structured Lifestyle Maintenance
Patients who combined GLP-1 therapy with behavioral counseling and structured dietary change retain more weight loss after stopping. Maintaining a protein-rich diet, regular exercise, and sleep hygiene can partially compensate for the loss of pharmacological appetite suppression.
Combining exercise with medication during treatment is particularly important — see Exercise with GLP-1 Medications: Preserving Muscle for evidence-based guidance on training while on these drugs.
3. Consider Alternative Pharmacotherapy
If semaglutide or tirzepatide becomes unavailable, other weight loss medications — while generally less effective — may provide a pharmacological bridge. Consult your physician before switching. For a comparison of switching strategies, see How to Switch Between GLP-1 Medications Safely.
4. Plan for Re-initiation
Patients who stop and regain should not view this as a failure. Re-initiating GLP-1 therapy — when clinically appropriate and accessible — tends to produce similar results to the initial treatment course.
Long-Term Treatment: The Emerging Consensus
Based on current evidence, the medical community is increasingly aligning on a key message: obesity is a chronic disease, and GLP-1 receptor agonists may need to be taken indefinitely — similar to antihypertensives or statins — to maintain their benefits.
The Obesity Society and major endocrinology guidelines now reflect this position. The framing of GLP-1 therapy as a "course of treatment" with a defined endpoint is inconsistent with what the biology and the trial data show.
This has significant implications for healthcare systems, insurers, and patients. Decisions about initiating GLP-1 therapy should be made with a clear understanding that stopping the medication is likely to result in regaining most of the lost weight — and that this is a biological consequence of the treatment, not a personal failing.
Key Takeaways
- Most people regain 2/3 or more of lost weight within one year of stopping semaglutide
- The STEP 1 extension showed only ~5.6% net weight loss sustained after 52 weeks off therapy
- SURMOUNT-4 data found 82.5% of tirzepatide-stop participants regained ≥25% of weight lost
- Cardiometabolic benefits reverse along with weight — blood pressure, blood sugar, and lipids worsen
- Weight regain is a biological response, not a behavioral failure
- Long-term or indefinite treatment may be required for sustained outcomes
- When stopping is unavoidable, lifestyle strategies and gradual tapering may help limit regain
References
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. DOI: 10.1111/dom.14725
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. DOI: 10.1001/jama.2021.3224
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. DOI: 10.1001/jama.2023.24945
Post Hoc SURMOUNT-4 Analysis. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Internal Medicine. 2025. DOI: 10.1001/jamainternmed.2025.6112 PubMed
Berg AS, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obesity Reviews. 2025. DOI: 10.1111/obr.13929 PubMed
Last updated: 2026-03-28 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.